LTC1663240I2 - Pirimidino deriniai, turintys nnrti su rt slopikliais - Google Patents

Pirimidino deriniai, turintys nnrti su rt slopikliais

Info

Publication number: LTC1663240I2
Authority: LT; Lithuania
Prior art keywords: pyrimidine; inhibitors; combinations containing; nnrti; containing nnrti
Prior art date: 2003-09-03

Application number

LTPA2015035C

Other languages

English (en)

Original Assignee

Janssen Sciences Ireland Uc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-03

Filing date

2016-12-20

Publication date

2022-05-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC1663240(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-12-20 Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc

2017-01-10 Publication of LTPA2016044I1 publication Critical patent/LTPA2016044I1/lt

2022-05-25 Publication of LTC1663240I2 publication Critical patent/LTC1663240I2/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

LTPA2015035C 2003-09-03 2016-12-20 Pirimidino deriniai, turintys nnrti su rt slopikliais LTC1663240I2 (lt)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US49977103P	2003-09-03	2003-09-03
EP03103275		2003-09-03
EP03103319		2003-09-08
EP03103335		2003-09-10
EP03103668		2003-10-02
US50848603P	2003-10-03	2003-10-03
PCT/EP2004/052028 WO2005021001A1 (en)	2003-09-03	2004-09-03	Combinations of a pyrimidine containing nnrti with rt inhibitors
EP04787096.9A EP1663240B2 (en)	2003-09-03	2004-09-03	Combinations of a pyrimidine containing nnrti with rt inhibitors

Publications (2)

Publication Number	Publication Date
LTPA2016044I1 LTPA2016044I1 (lt)	2017-01-10
LTC1663240I2 true LTC1663240I2 (lt)	2022-05-25

Family

ID=34280181

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTPA2016045C LTPA2016045I1 (lt)	2003-09-03	2016-12-20	Pirimidino deriniai, turintys NNRTI su RT slopikliais
LTPA2015035C LTC1663240I2 (lt)	2003-09-03	2016-12-20	Pirimidino deriniai, turintys nnrti su rt slopikliais

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTPA2016045C LTPA2016045I1 (lt)	2003-09-03	2016-12-20	Pirimidino deriniai, turintys NNRTI su RT slopikliais

Country Status (24)

Country	Link
US (9)	US20080200435A1 (lt)
EP (1)	EP1663240B2 (lt)
JP (3)	JP5507791B2 (lt)
KR (1)	KR20060090658A (lt)
CN (1)	CN101060844B (lt)
AP (1)	AP2109A (lt)
AU (5)	AU2004268390B2 (lt)
BE (1)	BE2015C053I2 (lt)
CA (1)	CA2537095C (lt)
CY (5)	CY2015038I1 (lt)
FI (1)	FI1663240T4 (lt)
FR (3)	FR15C0073I2 (lt)
HR (1)	HRP20150798T4 (lt)
HU (5)	HUS1500054I1 (lt)
IL (2)	IL173438A (lt)
LT (2)	LTPA2016045I1 (lt)
LU (3)	LU92853I2 (lt)
MX (1)	MXPA06002437A (lt)
MY (1)	MY169670A (lt)
NL (2)	NL300781I2 (lt)
NO (6)	NO334877B1 (lt)
NZ (1)	NZ545306A (lt)
PL (1)	PL1663240T5 (lt)
WO (1)	WO2005021001A1 (lt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
US8101629B2 (en)	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
WO2004016581A1 (en)	2002-08-09	2004-02-26	Janssen Pharmaceutica N.V.	Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
ATE398455T1 (de)	2003-01-14	2008-07-15	Gilead Sciences Inc	Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
KR101284361B1 (ko) *	2004-09-02	2013-07-15	얀센 파마슈티카 엔.브이.	4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
BRPI0514861A (pt) *	2004-09-02	2008-06-24	Janssen Pharmaceutica Nv	furamato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidi nil)amino)benzonitrila
AU2005279157B2 (en) *	2004-09-02	2011-07-14	Janssen Pharmaceutica N.V.	Fumarate of 4-[[4-[[4- (2-cyanoethenyl) -2,6-dimethylphenyl]amino)-2-pyrimidinyl)amino]benzonitrile
JP4912309B2 (ja) *	2004-09-02	2012-04-11	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの塩酸塩
CN101056673A (zh) *	2004-09-02	2007-10-17	詹森药业有限公司	4－[[4－[[4－(2－氰基乙烯基)－2,6－二甲基苯基]氨基]－2－嘧啶基]氨基]苄腈的盐酸盐
TW201414495A (zh) *	2005-04-04	2014-04-16	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
TWI375560B (en) *	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
JP5231242B2 (ja) *	2005-12-14	2013-07-10	シプラ・リミテッド	ヌクレオチド及びヌクレオシド系逆転写酵素阻害剤（テノホビル及びラミブジン）を剤形の異なる部分に含む医薬組合せ
EA014914B1 (ru) *	2006-01-20	2011-02-28	Тиботек Фармасьютикалз Лтд.	Долговременное лечение вич-инфекции
US9044509B2 (en) *	2006-02-03	2015-06-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr)	2006-07-05	2008-09-26	Univ Aix Marseille Ii	Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
TWI494133B (zh)	2007-03-14	2015-08-01	Tibotec Pharm Ltd	重組用粉末
CN101990432B (zh) *	2008-01-03	2016-01-20	艾克斯-马赛大学	抗hiv治疗期间使用的组合物和方法
SG172398A1 (en) *	2008-12-24	2011-07-28	Tibotec Pharm Ltd	Implantable devices for treating hiv
NZ600156A (en)	2009-12-21	2015-01-30	Janssen R & D Ireland	Degradable removable implant for the sustained release of an active compound
SI2932970T1 (en)	2010-01-27	2018-07-31	Viiv Healthcare Company	Antiviral therapy
UA114075C2 (xx) *	2010-11-19	2017-04-25		БАГАТОШАРОВА ТАБЛЕТКА, ЩО МІСТИТЬ РИЛПІВІРИН HCl, ЕМТРИЦИТАБІН І ТЕНОФОВІРУ ДИЗОПРОКСИЛФУМАРАТ
WO2012125993A1 (en)	2011-03-17	2012-09-20	Teva Pharmaceutical Industries Ltd.	Solid state forms of rilpivirine base, and rilipivirine salts
ES2680146T3 (es) *	2011-09-16	2018-09-04	Hetero Research Foundation	Hidrocloruro de rilpivirina
MY164352A (en)	2012-12-21	2017-12-15	Gilead Sciences Inc	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CA2948021C (en)	2015-11-09	2024-06-18	Gilead Sciences, Inc.	Pharmaceutical formulations of (2r,5s,13 ar)-8hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzy1)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1'2':4,5]pyrazino [2,1-b][1,3] oxazepine-10-carboxamide
KR20190073450A (ko)	2016-10-24	2019-06-26	얀센 사이언시즈 아일랜드 언리미티드 컴퍼니	분산성 조성물
WO2018119371A1 (en) *	2016-12-23	2018-06-28	Temple University - Of The Commonwealth System Of Higher Education	Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
EP3612226A1 (en) *	2017-04-18	2020-02-26	Cipla Limited	Combination therapy for use in treating retroviral infections
WO2019021319A1 (en) *	2017-07-27	2019-01-31	Cipla Limited	PHARMACEUTICAL COMPOSITIONS
CN115397422A (zh)	2019-11-29	2022-11-25	西皮欧生命科学有限公司	包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5182111A (en) *	1987-11-17	1993-01-26	Boston University Research Foundation	In vivo delivery of active factors by co-cultured cell implants
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en)	1988-06-27	1988-08-03	Wellcome Found	Therapeutic nucleosides
US5368864A (en) *	1988-11-25	1994-11-29	Henning Berlin Gmbh Chemie- Und Pharmawerk	Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en)	1989-12-22	1994-04-30	The Wellcome Foundation Ltd	Therapeutic nucleosides.
KR0172134B1 (ko)	1990-07-19	1999-02-01	오오쓰까 아끼히코	고형 제제
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
EP0610441A4 (en) *	1991-10-29	1996-01-10	Clover Cons Ltd	CROSSLINKABLE POLYSACCHARIDES, POLYCATIONS AND LIPIDS CAN BE USED TO ENCODE AND DISPENSE MEDICINAL PRODUCTS.
DK0639971T3 (da)	1992-05-13	2000-03-20	Wellcome Found	Terapeutiske kombinationer
JPH06316524A (ja)	1992-09-11	1994-11-15	Naoyuki Inoue	抗エイズウイルス剤
TW401303B (en) *	1994-07-01	2000-08-11	Janssen Pharmaceutica Nv	Anti-HIV triple combination
IT1281502B1 (it) *	1995-06-13	1998-02-18	Sardinian Antiviral Research C	Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) *	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
KR100801588B1 (ko)	1999-09-21	2008-02-05	스키에파마 캐나다 인코포레이티드	생물학적 유효 물질의 표면 변형된 미립자 조성물
US6743446B2 (en) *	1999-12-15	2004-06-01	The Ohio State University Research Foundation	Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TW200800298A (en) *	2000-01-27	2008-01-01	Zentaris Ag	Compressed microparticles for dry injection
CZ20023003A3 (cs)	2000-03-30	2002-11-13	Bristol-Myers Squibb Company	Perličky s trvalým uvolňováním obsahující stavudin
US20040115268A1 (en) *	2000-04-26	2004-06-17	Control Delivery Systems, Inc.	Systemic delivery of antiviral agents
DE10050199A1 (de)	2000-10-11	2002-04-25	Ethicon Gmbh	Flächiges Implantat mit im Ultraschall detektierbaren Elementen
CA2431319A1 (en)	2000-12-11	2002-06-20	Hiroto Bando	Pharmaceutical composition having an improved water solubility
ATE444060T1 (de)	2001-06-22	2009-10-15	Pfizer Prod Inc	Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) *	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
US20030166509A1 (en)	2001-11-20	2003-09-04	Advanced Inhalation Research, Inc.	Compositions for sustained action product delivery and methods of use thereof
WO2004016581A1 (en)	2002-08-09	2004-02-26	Janssen Pharmaceutica N.V.	Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AU2003278766A1 (en) *	2002-09-04	2004-03-29	Microchips, Inc.	Method and device for the controlled delivery of parathyroid hormone
ES2286471T3 (es)	2002-11-08	2007-12-01	Glaxo Group Limited	Composiciones farmaceuticas antivirales.
CA2506316A1 (en)	2002-11-15	2004-06-03	Tibotec Pharmaceuticals Ltd.	Substituted indolepyridinium as anti-infective compounds
AU2002350719A1 (en)	2002-11-29	2004-06-23	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
NZ541902A (en)	2003-02-07	2008-12-24	Janssen Pharmaceutica Nv	Pyrimidine derivatives for the prevention of HIV infection
KR100629771B1 (ko) *	2004-01-27	2006-09-28	씨제이 주식회사	결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
EP1765283A4 (en)	2004-06-08	2012-11-28	Vertex Pharma	PHARMACEUTICAL COMPOSITIONS
MY191349A (en)	2004-08-27	2022-06-17	Bayer Pharmaceuticals Corp	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
JP4912309B2 (ja)	2004-09-02	2012-04-11	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの塩酸塩
KR101284361B1 (ko)	2004-09-02	2013-07-15	얀센 파마슈티카 엔.브이.	4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
CA2587710C (en)	2004-11-16	2014-10-21	Elan Pharma International Ltd.	Injectable nanoparticulate olanzapine formulations
TW201414495A (zh)	2005-04-04	2014-04-16	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
JP2008538754A (ja) *	2005-04-11	2008-11-06	ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ	薬剤を含んだ所定のレイヤパターンを有する複層構造体
TW200710091A (en)	2005-04-11	2007-03-16	Tibotec Pharm Ltd	(1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
WO2006131806A2 (en)	2005-06-07	2006-12-14	Pfizer Products Inc.	Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
JP2009502969A (ja)	2005-07-28	2009-01-29	アイエスピーインヴェストメンツインコーポレイテッド	非晶質エファビレンツ及びその製造
EA014914B1 (ru)	2006-01-20	2011-02-28	Тиботек Фармасьютикалз Лтд.	Долговременное лечение вич-инфекции
FI3366278T3 (fi)	2006-06-23	2024-09-25	Janssen Sciences Ireland Unlimited Co	Tmc278: n vesisuspensioita
WO2008060360A2 (en) *	2006-09-28	2008-05-22	Surmodics, Inc.	Implantable medical device with apertures for delivery of bioactive agents
TWI494133B (zh)	2007-03-14	2015-08-01	Tibotec Pharm Ltd	重組用粉末
JP5701057B2 (ja)	2007-07-12	2015-04-15	ヤンセンサイエンシズアイルランドユーシー	（ｅ）４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの結晶形
WO2009046299A2 (en)	2007-10-04	2009-04-09	Boston Scientific Scimed, Inc	Implantable drug depot for intrathecal drug delivery system for pain management
EP2358198A4 (en) *	2008-10-24	2012-11-14	Concert Pharmaceuticals Inc	HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES

2004
- 2004-09-02 MY MYPI20043578A patent/MY169670A/en unknown
- 2004-09-03 AU AU2004268390A patent/AU2004268390B2/en not_active Expired
- 2004-09-03 PL PL04787096.9T patent/PL1663240T5/pl unknown
- 2004-09-03 CN CN2004800254267A patent/CN101060844B/zh not_active Expired - Lifetime
- 2004-09-03 CA CA2537095A patent/CA2537095C/en not_active Expired - Lifetime
- 2004-09-03 KR KR1020067003074A patent/KR20060090658A/ko not_active Ceased
- 2004-09-03 EP EP04787096.9A patent/EP1663240B2/en not_active Expired - Lifetime
- 2004-09-03 JP JP2006525150A patent/JP5507791B2/ja not_active Expired - Lifetime
- 2004-09-03 US US10/570,228 patent/US20080200435A1/en not_active Abandoned
- 2004-09-03 NZ NZ545306A patent/NZ545306A/en not_active IP Right Cessation
- 2004-09-03 WO PCT/EP2004/052028 patent/WO2005021001A1/en active Application Filing
- 2004-09-03 MX MXPA06002437A patent/MXPA06002437A/es active IP Right Grant
- 2004-09-03 AP AP2006003551A patent/AP2109A/en active
2006
- 2006-01-30 IL IL173438A patent/IL173438A/en active Protection Beyond IP Right Term
- 2006-03-27 NO NO20061374A patent/NO334877B1/no active Protection Beyond IP Right Term
2009
- 2009-10-07 US US12/574,881 patent/US8841310B2/en active Active
2011
- 2011-03-14 AU AU2011201123A patent/AU2011201123B2/en not_active Expired
- 2011-05-24 IL IL213104A patent/IL213104A/en active IP Right Grant
- 2011-10-12 JP JP2011224982A patent/JP2012051915A/ja not_active Withdrawn
2014
- 2014-06-26 AU AU2014203484A patent/AU2014203484B2/en active Active
- 2014-08-07 US US14/454,045 patent/US20140349971A1/en not_active Abandoned
- 2014-10-31 JP JP2014222770A patent/JP5820045B2/ja not_active Expired - Lifetime
- 2014-12-18 NO NO2014030C patent/NO2014030I1/no unknown
- 2014-12-18 NO NO2014032C patent/NO2014032I1/no unknown
- 2014-12-18 NO NO2014031C patent/NO2014031I1/no not_active IP Right Cessation
2015
- 2015-06-19 US US14/744,501 patent/US20150283135A1/en not_active Abandoned
- 2015-07-20 HR HRP20150798TT patent/HRP20150798T4/hr unknown
- 2015-10-20 NL NL300781C patent/NL300781I2/nl unknown
- 2015-10-20 LU LU92853C patent/LU92853I2/xx unknown
- 2015-10-21 FR FR15C0073C patent/FR15C0073I2/fr active Active
- 2015-10-21 CY CY2015038C patent/CY2015038I1/el unknown
- 2015-10-21 HU HUS1500054C patent/HUS1500054I1/hu unknown
- 2015-10-21 FR FR15C0071C patent/FR15C0071I2/fr active Active
- 2015-10-21 HU HUS1500052C patent/HUS1500052I1/hu unknown
- 2015-10-21 LU LU92855C patent/LU92855I2/xx unknown
- 2015-10-21 FR FR15C0072C patent/FR15C0072I2/fr active Active
- 2015-10-21 CY CY2015040C patent/CY2015040I2/el unknown
- 2015-10-21 CY CY2015039C patent/CY2015039I1/el unknown
- 2015-10-21 LU LU92854C patent/LU92854I2/xx unknown
- 2015-10-21 HU HUS1500053C patent/HUS1500053I1/hu unknown
- 2015-10-21 BE BE2015C053C patent/BE2015C053I2/fr unknown
- 2015-10-21 NL NL300768C patent/NL300768I2/nl unknown
2016
- 2016-08-05 AU AU2016210733A patent/AU2016210733B2/en active Active
- 2016-12-19 US US15/383,076 patent/US20170100398A1/en not_active Abandoned
- 2016-12-20 LT LTPA2016045C patent/LTPA2016045I1/lt unknown
- 2016-12-20 NO NO2016025C patent/NO2016025I1/no unknown
- 2016-12-20 FI FIEP04787096.9T patent/FI1663240T4/fi active
- 2016-12-20 HU HUS1600059C patent/HUS1600059I1/hu unknown
- 2016-12-20 CY CY2016049C patent/CY2016049I2/el unknown
- 2016-12-20 HU HUS1600058C patent/HUS1600058I1/hu unknown
- 2016-12-20 LT LTPA2015035C patent/LTC1663240I2/lt unknown
- 2016-12-20 NO NO2016026C patent/NO2016026I1/no unknown
- 2016-12-20 CY CY2016048C patent/CY2016048I1/el unknown
2018
- 2018-04-11 US US15/950,548 patent/US20180228800A1/en not_active Abandoned
2019
- 2019-02-06 AU AU2019200813A patent/AU2019200813A1/en not_active Abandoned
- 2019-03-21 US US16/360,693 patent/US20190216807A1/en not_active Abandoned
2020
- 2020-02-07 US US16/784,404 patent/US20200171027A1/en not_active Abandoned
2021
- 2021-09-13 US US17/472,870 patent/US20220008417A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CY2015039I2 (el)	2016-08-31
FR15C0073I2 (fr)	2016-02-12
EP1663240A1 (en)	2006-06-07
HK1092698A1 (en)	2007-02-16
CA2537095A1 (en)	2005-03-10
JP5507791B2 (ja)	2014-05-28
CY2016049I1 (el)	2017-07-12
HUS1500052I1 (hu)	2016-03-29
AU2014203484A1 (en)	2014-07-17
US20080200435A1 (en)	2008-08-21
JP2012051915A (ja)	2012-03-15
US20190216807A1 (en)	2019-07-18
NO2014030I1 (no)	2015-01-05
JP5820045B2 (ja)	2015-11-24
HUS1500053I1 (hu)	2016-03-29
US20150283135A1 (en)	2015-10-08
AU2004268390A1 (en)	2005-03-10
BE2015C053I2 (lt)	2023-12-14
HRP20150798T4 (hr)	2023-06-09
US20170100398A1 (en)	2017-04-13
IL173438A (en)	2012-03-29
FR15C0072I2 (fr)	2019-05-17
EP1663240B2 (en)	2023-03-01
AU2014203484B2 (en)	2016-09-29
FR15C0071I2 (fr)	2016-02-12
AU2011201123B2 (en)	2013-10-10
WO2005021001A1 (en)	2005-03-10
CA2537095C (en)	2012-05-29
NL300781I1 (lt)	2016-04-19
US20140349971A1 (en)	2014-11-27
CY2015038I2 (el)	2016-08-31
FR15C0071I1 (lt)	2015-04-12
CY2015038I1 (el)	2016-08-31
NO2016026I1 (no)	2016-12-20
NO2014030I2 (no)	2014-12-18
CN101060844B (zh)	2012-01-04
US8841310B2 (en)	2014-09-23
US20220008417A1 (en)	2022-01-13
NL300768I1 (lt)	2015-12-16
CY2015040I1 (el)	2016-08-31
IL173438A0 (en)	2006-06-11
AU2016210733A1 (en)	2016-08-25
LTPA2016044I1 (lt)	2017-01-10
MY169670A (en)	2019-05-08
IL213104A0 (en)	2011-07-31
LU92855I2 (fr)	2015-12-21
AU2019200813A1 (en)	2019-02-28
MXPA06002437A (es)	2006-06-20
IL213104A (en)	2016-02-29
HUS1600059I1 (hu)	2017-02-28
NO2014031I2 (no)	2014-12-18
AP2006003551A0 (en)	2006-04-30
LU92853I2 (fr)	2015-12-21
LTPA2016045I1 (lt)	2017-01-10
NO2014032I2 (no)	2014-12-18
JP2015044839A (ja)	2015-03-12
AU2004268390B2 (en)	2011-03-31
FR15C0073I1 (lt)	2015-04-12
AU2016210733B2 (en)	2018-11-08
AU2011201123A1 (en)	2011-04-07
PL1663240T3 (pl)	2015-10-30
JP2007520443A (ja)	2007-07-26
HUS1500054I1 (hu)	2016-03-29
US20100029591A1 (en)	2010-02-04
NO2016025I1 (lt)	2016-12-20
KR20060090658A (ko)	2006-08-14
NL300781I2 (lt)	2016-04-19
CN101060844A (zh)	2007-10-24
PL1663240T5 (pl)	2024-02-26
NL300768I2 (nl)	2023-08-09
HRP20150798T1 (hr)	2015-09-11
LU92854I2 (fr)	2015-12-21
NO2014032I1 (no)	2015-01-05
CY2015039I1 (el)	2016-08-31
HUS1600058I1 (hu)	2017-02-28
CY2016049I2 (el)	2017-07-12
CY2016048I2 (el)	2017-07-12
CY2016048I1 (el)	2017-07-12
EP1663240B1 (en)	2015-04-22
FI1663240T4 (fi)	2023-04-25
NZ545306A (en)	2009-11-27
NO334877B1 (no)	2014-06-23
NO2014031I1 (no)	2015-01-05
NO20061374L (no)	2006-03-27
US20200171027A1 (en)	2020-06-04
FR15C0072I1 (lt)	2015-04-12
AP2109A (en)	2010-02-26
US20180228800A1 (en)	2018-08-16
CY2015040I2 (el)	2016-08-31

Publication	Publication Date	Title
LTC1663240I2 (lt)	2022-05-25	Pirimidino deriniai, turintys nnrti su rt slopikliais
NL2000323A1 (nl)	2007-06-21	Pyrimidine-derivaten.
DK1761505T3 (da)	2011-12-05	Pyrimidin-urinstof-derivater som kinaseinhibitorer
DE60313872D1 (de)	2007-06-28	Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
DK1487805T3 (da)	2012-10-15	Pyrimidinderivater
DE602004012154D1 (de)	2008-04-10	Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren
ATE512960T1 (de)	2011-07-15	Pyrimidinderivate
DK1544379T3 (da)	2014-07-07	Klemindretning
DE602005002716D1 (de)	2007-11-15	Haltevorrichtung
DE502004002049D1 (de)	2007-01-04	Halteeinrichtung
NO20055023L (no)	2005-12-06	Hurtigskytende vapen
DE112004001801D2 (de)	2006-06-01	Haltevorrichtung
ES1059189Y (es)	2005-07-01	Bolsillo.
AT500804B1 (de)	2006-07-15	Abstandhalter
DE602004004185D1 (de)	2007-02-22	Klammer
ES1058704Y (es)	2005-05-16	Antirrobo porta-esquies.
ES1053882Y (es)	2003-09-01	Hamaca colgante.
SE0400584D0 (sv)	2004-03-09	NNRTI Antivirals II
ITBO20040669A1 (it)	2005-01-28	Supporto portapane con oliera
SE0301098D0 (sv)	2003-04-11	Dubbelhållare
SE0400585D0 (sv)	2004-03-09	NNRTI Antivirals
ITPD20030088A1 (it)	2004-11-03	Piedino strutturale reggicartello.
AT500742B1 (de)	2006-07-15	Abstandhalter
AT500805B8 (de)	2007-02-15	Abstandhalter
AT500803B8 (de)	2007-02-15	Abstandhalter